
Hikma Pharma to pay $50 million to settle narcolepsy drug antitrust case
By Mike Scarcella (Reuters) – Hikma Pharmaceuticals has agreed to pay $50 million to settle a class action accusing the drugmaker of scheming to delay a generic version of Jazz’s blockbuster narcolepsy drug Xyrem, causing health plans to pay higher prices. …